Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA; SARCOMA | Neoplastic Lesions |
Yes | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA; SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA | Neoplastic Lesions |
Yes | TR-207 | 21739-91-3 | Cytembena | Rats | F344/N | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 37/50 36/50 | Neoplastic Lesions |
Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 7/50 25/50 | Neoplastic Lesions |
Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | 0/50 1/50 4/50 | Neoplastic Lesions |
Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/60 0/45 3/75 4/60 | Neoplastic Lesions |
Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | SARCOMA 0/50 4/50 8/50 3/50 | Neoplastic Lesions |
Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50 | Neoplastic Lesions |
Yes | TR-483 | 87-86-5 | Pentachlorophenol, purified | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Some Evidence | Some Evidence | MESOTHELIOMA 1/50 0/50 2/50 0/50 9/50 (STOP STUDY) | Neoplastic Lesions |
Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60 | Neoplastic Lesions |
Yes | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Some Evidence | Equivocal Evidence | Malignant: 0/50 2/50 2/50 4/50 | May Have Been Related |
Yes | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | Malignant Mesothelioma 1/50 5/50 10/50 6/50 | Neoplastic Lesions |
Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Female | Inhalation | Intestines (Large) | Clear Evidence | Clear Evidence | Adenoma 0/50 1/50 2/50 5/50 | Neoplastic Lesions |
No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Intestines (Large) | Some Evidence | Some Evidence | Adenoma 0/50 0/50 2/50 1/50 | Neoplastic Lesions |
No | TR-564 | 106-94-5 | 1-Bromopropane | Mice | B6C3F1/N | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/bronchiolar adenoma 1/50 6/50 4/50 10/50 alveolar/bronchiolar carcinoma 0/50 7/50 5/50 4/50 alveolar/bronchiolar adenoma or carcinoma 1/50 9/50 8/50 14/50 | Neoplastic Lesions |
Yes | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Some Evidence | Equivocal Evidence | Malignant: 0/50 2/50 2/50 4/50 | May Have Been Related |
No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Pancreas Islet Cell | Some Evidence | Equivocal Evidence | Adenoma 0/50 5/50 4/50 5/50 | May Have Been Related |
No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Female | Inhalation | Skin | Clear Evidence | Equivocal Evidence | Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 1/50 1/50 1/50 4/50 | May Have Been Related |
No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Skin | Some Evidence | Some Evidence | Keratoacanthoma 0/50 3/50 6/50 6/50 keratoacanthoma or squamous cell carcinoma 1/50 4/50 6/50 8/50 keratoacanthoma, basal cell adenoma or carcinoma or squamous cell carcinoma 1/50 7/50 9/50 10/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 7/49 13/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/49 5/49 37/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Male | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 0/41 0/48 11/46; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/41 3/48 19/46 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 1/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/48 4/47 COMBINED 0/50 0/48 5/47 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Positive | Positive | ADENOCARCINOMA 2/50 14/50 8/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Positive | Positive | FIBROADENOMA 4/50 29/50 24/50 | Neoplastic Lesions |
Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 7/50 25/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Nasal Cavity | Positive | Positive | CARCINOMA 0/50 0/50 6/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Nasal Cavity | Positive | Positive | ADENOMA 0/50 11/50 3/50; ADENOCARCINOMA 0/50 20/50 29/50; CARCINOMA 0/50 0/50 25/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Nasal Cavity | Positive | Positive | ADENOMA 0/50 11/50 0/50; ADENOCARCINOMA 0/50 20/50 28/50; CARCINOMA 0/50 0/50 21/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Positive | Positive | FIBROSARCOMA 0/50 5/50 11/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 11/50 23/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 0/50 5/50 | Neoplastic Lesions |
No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 1/50 15/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50 | May Have Been Related |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/50 5/50 | Neoplastic Lesions |
Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | 0/50 1/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 44/50 49/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 48/50 48/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60 | Neoplastic Lesions |
No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60 | May Have Been Related |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60 | May Have Been Related |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60 | May Have Been Related |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/60 1/45 3/75 6/60 | Neoplastic Lesions |
Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/60 0/45 3/75 4/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60 | Neoplastic Lesions |
No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60 | Neoplastic Lesions |
No | TR-049 | 7008-42-6 | Acronycine | Mice | B6C3F1 | Female | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
No | TR-049 | 7008-42-6 | Acronycine | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
No | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Bone | Positive | Positive | (OSTEOSARCOMA) | Neoplastic Lesions |
No | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
Yes | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA; SARCOMA | Neoplastic Lesions |
Yes | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA; SARCOMA | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | Squamous Cell Papilloma 0/50 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Lung | Clear Evidence | Equivocal Evidence | Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50 | May Have Been Related |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 3/50 4/50 7/50 12/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 24/49 32/50 36/50 36/50 | Neoplastic Lesions |
Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | SARCOMA 0/50 4/50 8/50 3/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 11/50 11/50 18/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Urinary Bladder | Clear Evidence | Equivocal Evidence | TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50 | May Have Been Related |
No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Urinary Bladder | Clear Evidence | Equivocal Evidence | TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49 | May Have Been Related |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Unspecified) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Unspecified) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50 | Neoplastic Lesions |
No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 3/50 | Neoplastic Lesions |
No | TR-207 | 21739-91-3 | Cytembena | Mice | B6C3F1 | Female | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
No | TR-207 | 21739-91-3 | Cytembena | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
No | TR-207 | 21739-91-3 | Cytembena | Rats | F344/N | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | FIBROADENOMA 13/49 22/50 36/50 | Neoplastic Lesions |
Yes | TR-207 | 21739-91-3 | Cytembena | Rats | F344/N | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 37/50 36/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50 | May Have Been Related |
No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 5/50 5/50 15/50 13/50 6/50 | Neoplastic Lesions |
Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50 | Neoplastic Lesions |
No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/60 2/60 3/60 50/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 4/60 17/60 55/60 60/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (CECUM) CARCINOMA 0/60 1/60 4/60 3/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (CECUM) CARCINOMA 0/60 12/60 9/60 0/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Liver | Clear Evidence | Equivocal Evidence | ADENOMA 1/60 0/59 1/60 6/60 | May Have Been Related |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 23/60 47/60 52/60 56/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60 | Neoplastic Lesions |
Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60 | Neoplastic Lesions |
No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60 | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOMA OR FIBROADENOMA) | Neoplastic Lesions |
Yes | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Spleen | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Spleen | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Urinary Bladder | Positive | Positive | (TRANSITIONAL CELL CARCINOMA) | Neoplastic Lesions |
No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Mice | B6C3F1 | Male | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
No | TR-483 | 87-86-5 | Pentachlorophenol, purified | Rats | F344/N | Female | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
Yes | TR-483 | 87-86-5 | Pentachlorophenol, purified | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Some Evidence | Some Evidence | MESOTHELIOMA 1/50 0/50 2/50 0/50 9/50 (STOP STUDY) | Neoplastic Lesions |
No | TR-483 | 87-86-5 | Pentachlorophenol, purified | Rats | F344/N | Male | Dosed-Feed | Nasal Cavity | Some Evidence | Some Evidence | CARCINOMA 1/50 3/50 1/50 0/50 5/50 (STOP STUDY) | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-072 | 63-92-3 | Phenoxybenzamine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | SARCOMA | Neoplastic Lesions |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | Adenoma 0/50 0/50 3/50 7/50 | Neoplastic Lesions |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | Adenoma 0/50 2/50 0/50 4/50 | Neoplastic Lesions |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Equivocal Evidence | Adenoma 0/50 0/50 0/50 3/50 | May Have Been Related |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Equivocal Evidence | Adenoma 2/50 0/50 3/50 4/50 | May Have Been Related |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Mice | B6C3F1/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | Adenoma 27/50 48/50 44/50 46/50 carcinoma 14/50 23/50 26/50 20/50 adenoma or carcinoma 31/50 49/50 46/50 46/50 | Neoplastic Lesions |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Mice | B6C3F1/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | Adenoma 27/50 40/50 40/50 31/50 carcinoma 19/50 25/50 36/50 45/50 adenoma or carcinoma 34/50 44/50 49/50 49/50 hepatoblastoma 4/50 11/50 28/50 34/50 | Neoplastic Lesions |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | Fibroadenoma, multiple 22/50 24/50 43/50 38/50 | Neoplastic Lesions |
Yes | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | Malignant Mesothelioma 1/50 5/50 10/50 6/50 | Neoplastic Lesions |
No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Pancreas Islet Cell | Clear Evidence | Equivocal Evidence | Adenoma 3/50 4/50 9/50 3/50 | May Have Been Related |